Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:2.7.12.2 (
MEK
)
18,161
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Aberrant function of
RRAS2
drives malignant transformation in a various of cancers. However, little information exists on the function of
RRAS2
in tumorigenesis of osteosarcoma. In this study, we investigated the effect of
RRAS2
on osteosarcoma progression and its underlying mechanism. The gene expression level and prognostic power of
RRAS2
in osteosarcoma were first investigated using the data from the Gene Expression Omnibus database. Then RNA interference was performed to silence the expression of
RRAS2
in osteosarcoma cells. Quantitative real-time-PCR and western blot were used to examine the gene and protein expressions of
RRAS2
in osteosarcoma cells. In-vitro cancer proliferation and migration were determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolum bromide solution and wound-healing assays, respectively. We found that
RRAS2
was significantly upregulated in osteosarcoma cells and high expression of
RRAS2
was associated with a poor prognosis for patients with osteosarcoma. RNA interference decreased the gene and protein expression of
RRAS2
, reduced in-vitro the proliferation and migration of osteosarcoma cells, and suppressed the activation of the
MEK
/ERK signaling pathway.
RRAS2
as an adverse prognostic factor promoted cell proliferation and migration by activating the
MEK
/ERK signaling pathway, and may provide new therapeutic value for osteosarcoma.
...
PMID:RRAS2 knockdown suppresses osteosarcoma progression by inactivating the MEK/ERK signaling pathway. 3151 33
